Navigation Links
Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
Date:10/17/2010

SAN CARLOS, Calif., Oct. 17 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today presented new preclinical data demonstrating that NKTR-181, a mu-opioid analgesic with a novel molecular structure, dramatically reduces abuse liability while providing analgesia comparable to oxycodone and morphine.  These data were presented during the poster session entitled "Chronic and Cancer Pain" held today at the American Society of Anesthesiologists (ASA 2010) Annual Meeting on October 17, 2010 in San Diego, CA.

NKTR-181 was uniquely designed to cross the blood-brain barrier at a substantially slower rate than other opioid therapies.  With a reduced rate of entry into the CNS, NKTR-181 has the potential to eliminate not only the euphoria that underlies opioid abuse liability and dependence but also the serious CNS-related side effects of respiratory depression and sedation. The unique molecular design of the polymer drug conjugate also prevents conversion of NKTR-181 by the user into a rapid-acting abusable form of an opioid.  NKTR-181 is currently in IND-enabling studies and Nektar plans to begin Phase 1 clinical studies in the first part of 2011.  

"New therapeutics to manage chronic pain without the serious risks associated with existing opioids are desperately needed," said Lynn R. Webster, MD, Medical Director of Lifetree Clinical Research and Pain Clinic and President, Utah Academy of Pain Medicine.  "A novel opioid therapy, such as NKTR-181, with low abuse potential and fewer CNS-related side effects than existing opioids provides great promise for pain practitioners looking for safer, more effective pain management."

NKTR-181 Data Highlights from ASA 2010In a preclinical in vivo model of pain, NKTR-181 showed comparable analgesic efficacy to both oxycodone and morphine.   In self-administration studies in non-human
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
9. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
10. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
11. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014  Pressure BioSciences, Inc. (OTCQB: ... has received and approved all parts required to ... has begun to manufacture the new PCT-based instrument ... be ready for shipment by mid-October and that ... at a rate of about one per week ...
(Date:9/19/2014)... 19, 2014 Aufgrund der ... äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, der jetzt auch die ... verfügbar unter pharmaserialisation.com , zeigt die Serialisierungsanforderungen ... in Kraft treten. Für international tätige ... um das "ob", sondern darum, "wann" sie die ...
(Date:9/19/2014)... and CAMBRIDGE, Mass. ... Inc. (PGDx), a provider of advanced cancer ... Medicines , a leader in discovering and developing ... today disclosed the first-ever comprehensive genomic study of ... deadly cancer of the female reproductive system, also ...
Breaking Medicine Technology:Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
... , , , ... HBP; OTCQX: HXBPF) today announced financial results for the first ... HIGHLIGHTS , DOS47/L-DOS47 , Helix announced that a ... Food and Drug Administration ("FDA") in which the FDA generally ...
... ... new market research report is available in its catalogue: , ... , http://www.reportlinker.com/p0164322/Medical-Fiber-Optics---A-World-Market-Analysis.html , Fiber optics work on ... enclosed in an element encased by glass in air of ...
Cached Medicine Technology:Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 2Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 3Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 4Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 5Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 6Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 7Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 8Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 9Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 10Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 11Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 12Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 13Reportlinker Adds Medical Fiber Optics - A World Market Analysis 2Reportlinker Adds Medical Fiber Optics - A World Market Analysis 3Reportlinker Adds Medical Fiber Optics - A World Market Analysis 4Reportlinker Adds Medical Fiber Optics - A World Market Analysis 5Reportlinker Adds Medical Fiber Optics - A World Market Analysis 6
(Date:9/20/2014)... Everett, WA (PRWEB) September 20, 2014 “Motherhood ... Health Center of Snohomish in their latest article , ... the best that you can—and that’s what we want to ... what services they need and should expect from their Family ... the following days of new motherhood. , To learn ...
(Date:9/19/2014)... Nearly 780 Risperdal lawsuits are moving forward in ... took place to discuss the next steps in ... mass tort program. Attorneys for the plaintiffs and defendants ... Complex Litigation Center in Philadelphia’s City Hall where the ... lawsuits filed against Johnson & Johnson and its subsidiary, ...
(Date:9/19/2014)... 19, 2014 Are you tired of ... problems with seasonal allergies or sinus congestion? Fortunately, an ... alternative. , She conceived of Nose Pal to ... runny nose in public. Since it prevents nasal drip ... sanitary conditions, particularly when cooking or working closely with ...
(Date:9/19/2014)... 19, 2014 (HealthDay News) -- As kids transition from ... of cyberbullies, according to a recent study. ... through 8 found that verbal and physical bullying declines ... bullying intervention and prevention strategies must address all types ... boys and girls, the researchers said. The study was ...
(Date:9/19/2014)... 19, 2014 Hastings and Hastings, a discount ... the industry, announces a record number of visitors to its ... variety of serious injury cases as well as auto accident ... bite related accident cases and others. Having served the state ... stood the test of time when it comes to dedicated ...
Breaking Medicine News(10 mins):Health News:Newest Article from Community Health Center of Snohomish County Highlights The Importance of Proper Health Care for Expectant Mothers 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 3Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 4Health News:Nasal Drip Eliminator Invented by InventHelp Client (LCC-218) 2Health News: Cyberbullying Seems to Ramp Up in Middle School 2Health News:Hastings And Hastings Announces a Record Number of Visitors to Its New Phoenix Personal Injury Website 2
... help those who have it, to live really long.// Strangely ... mental faculties also. This new research work was presented by ... University. December 26, 2006 issue of Neurology published their findings. ... of the Institute for Aging Research at Einstein. He along ...
... surgery years ago underwent the same procedure that he ... raring to get back to work after recuperating from the ... called aorta, in his heart ,that was torn. ,DeBakey ... for a condition called dissecting aortic aneurysm.As a young doctor ...
... Xylitol is a mint flavored sweetener, produced naturally by plants ... as an ingredient in chewing gum, toothpaste, mouthwash and other ... Research Service (ARS) and collaborators have developed a genetically engineered ... be used to produce Xylitol on a large scale. ...
... Salmonella enteriditis (SE) is present in eggs sometimes, and when ... eaten, may cause illness. The FDA (The U. S. Food ... bacteria and follow food safety practices to avoid egg-related illness. ... homemade eggnog, and some types of stuffing, contain eggs that ...
... from human kidney stones in cell cultures//and have isolated ... with nanoparticles. ,The findings, which appear in ... are significant because it is one step closer in ... forms that can lead to disease -- in this ...
... An Italian, Mario Scaramella who met - ex-KGB agent - ... radiation poisoning was arrested.// ,He was arrested on ... Rome, the man's father, Amedeo Scaramella said. ,Scaramella, ... to be arrested, met Litvinenko at a London sushi bar ...
Cached Medicine News:Health News:You may Live Long and Think Clear With a Variant Gene 2Health News:Pioneer Heart Surgeon Faced the Scalpel at 98 2Health News:Xylitol To Be Produced By Genetically Engineered E. Coli 2Health News:Link Between Nanoparticles and Kidney Stones 2Health News:Link Between Nanoparticles and Kidney Stones 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: